Akums Drugs & Pharmaceuticals Ltd (AKUMS)
·Next Day Close·-2.3%·₹800.2
Key EventTrading window closes before quarterly results
Akums Drugs & Pharmaceuticals Ltd (AKUMS)
·Next Day Close·-0.69%·₹818.05
Key EventCompany schedules institutional investor meetings for September 28-29, 2026
ImpactThese meetings provide direct engagement opportunities with institutional investors without new financial disclosures.Sign up to read impact
Akums Drugs & Pharmaceuticals Ltd (AKUMS)
·Next Day Close·-0.74%·₹766.15
Key EventCompany schedules investor/analyst meet for September 22, 2026
ImpactThis meet provides a platform for direct engagement with analysts and investors without new financial disclosures.Sign up to read impact
Akums Drugs & Pharmaceuticals Ltd (AKUMS)
·Next Day Close·-2.02%·₹765.7
Key EventCompany receives ESG rating of 65 from NSE Sustainability
ImpactThe ESG rating reflects moderate sustainability performance but does not directly affect financial results or shareholder value.Sign up to read impact
Akums Drugs and Pharmaceuticals Limited (AKUMS)
·Next Day Close·+2.78%·₹765.9
Key EventCompany announces scheduled investor/analyst meet participation
ImpactThese meetings provide direct engagement opportunities with institutional investors and analysts without new financial disclosures.Sign up to read impact
Akums Drugs and Pharmaceuticals Limited (AKUMS)
·Next Day Close·-3.25%·₹745.15
Key EventManagement cancels participation in investor meet due to medical reasons
ImpactShareholders should note the management's absence may limit insights into near-term strategy during the meet.Sign up to read impact
Akums Drugs and Pharmaceuticals Limited (AKUMS)
·Next Day Close·-3.24%·₹727.25
Key EventCompany announces investor conference participation
ImpactThis event provides a platform for market participants to engage with management without new financial disclosures.Sign up to read impact
Akums Drugs and Pharmaceuticals Limited (AKUMS)
·Next Day Close·+4.07%·₹761
Key EventCRISIL Monitoring Agency Report confirms full IPO proceeds utilization by Akums Drugs and Pharmaceuticals Limited for the quarter ended June 30, 2026.
ImpactAll IPO funds were deployed as planned with no unused proceeds remaining.Sign up to read impact
Akums Drugs and Pharmaceuticals Limited (AKUMS)
·Next Day Close·+4.07%·₹761
Key EventAudio recording of investor conference call released
ImpactShareholders can now review management's commentary on Q1 FY27 results via the provided audio link.Sign up to read impact
Akums Drugs and Pharmaceuticals Limited (AKUMS)
·Next Day Close·+4.99%·₹731.25
Key EventQ1 FY27 results show 13.9% revenue growth and 35.4% EBITDA increase.
ImpactShareholders see stronger profitability from CDMO and API segments, with strategic expansion into skincare through the Oriflame acquisition.Sign up to read impact